Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

SPDR S&P Pharmaceuticals ETF (NY: XPH )

43.12 UNCHANGED
Streaming Delayed Price Updated: 8:00 PM EDT, Mar 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 43.12
Bid (Size) 39.18 (1)
Ask (Size) 45.00 (1)
Prev. Close 43.12
Today's Range 43.12 - 43.12
52wk Range 38.88 - 48.76
Shares Outstanding 36,502
Dividend Yield 1.81%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Xeris Biopharma Stock Soars To Nearly 4-Year High On Strong 2025 Outlook, Retail Bulls Charge In
The company expects full-year revenue of $255 million to $275 million, significantly higher than the $239.77 million analysts had expected. 
Via Stocktwits
Esperion Therapeutics Retail Bulls Charge In As Stock Notches Best Day In 3 Months On Impressive Q4
CEO Sheldon Koenig expects to drive further revenue gains and reach operating profitability through the expansion of its bempedoic acid products in the U.S. and Europe and global expansion into key... 
Via Stocktwits

Performance

YTD
+1.13%
+1.13%
1 Month
-3.64%
-3.64%
3 Month
-4.77%
-4.77%
6 Month
-0.30%
-0.30%
1 Year
+0.87%
+0.87%

More News

Read More
Perrigo Outlines 2025 Growth Plans, Projects Sales Boost And Margin Expansion By 2027
Via Benzinga
Ken Griffin's Citadel Places Big Short Bet Against GSK - Here's What It Means for Investors
Via Benzinga
Mind Medicine Stock Rises As Evercore Projects 200% Upside On LSD Formulation: Retail Turns Bullish
Via Stocktwits
AstraZeneca Shares Fall Despite EPS Beat and Raised Guidance
Via MarketBeat
Topics ETFs
Purdue Pharma Bankruptcy Plan Rejected by Supreme Court, Billionaire Sacklers to Face Lawsuits
Via Benzinga
Topics Bankruptcy Lawsuit
Exposures Financial Legal
A Look At Pharma ETFs Post Q1 Earnings
Via Talk Markets
Topics ETFs
Organon Beats On Q1, Women's Health Leads the Charge
Via Benzinga
A Look At Pharma ETFs After Q4 Earnings
Via Talk Markets
Topics ETFs
How Much Pain Will Lower Medicare Prices Cause for Pharma Stocks?
Via MarketBeat
Topics Economy
Exposures Interest Rates
Pharma ETFs in Focus Post Q2 Earnings
Via Talk Markets
Topics ETFs
Pharma ETFs Gain Post Q1 Earnings
Via Talk Markets
A Look At Pharma ETFs Post Q4 Earnings
Via Talk Markets
Pharma ETFs In Focus Post Q3 Earnings
Via Talk Markets
Large Cap Biopharma- Well Positioned For Choppy Markets
Via Talk Markets
3 Pharma Stocks Yielding Over 3%
Via Talk Markets
7 Pharmaceutical Stocks That Could Make You Rich
Via InvestorPlace
The Bear Market Is Already Here – But Not For Dividend Investors
Via Talk Markets
Wave of Solid Q3 Earnings Push Pharma ETFs Higher
Via Talk Markets
The Cost Of Saving The Economy: $1.7 Billion Per Hour Every Hour
Via Talk Markets
Topics Bonds Economy
Exposures Debt Markets Interest Rates
The 2 Best Pharma Stocks to Buy on Dips
Via Talk Markets
Exposures COVID-19
3 Top Pharma Stocks to Buy This Month
Via Talk Markets
Pharma ETFs in Focus Post Q1 Earnings
Via Talk Markets
3 Pharmaceutical ETFs That Could Be Due For A Rebound
Via Talk Markets
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.